ZA200006685B - A hepatocyte targeting polyethylene Glyco-grafted poly-l-lysine polymeric gene carrier. - Google Patents

A hepatocyte targeting polyethylene Glyco-grafted poly-l-lysine polymeric gene carrier.

Info

Publication number
ZA200006685B
ZA200006685B ZA200006685A ZA200006685A ZA200006685B ZA 200006685 B ZA200006685 B ZA 200006685B ZA 200006685 A ZA200006685 A ZA 200006685A ZA 200006685 A ZA200006685 A ZA 200006685A ZA 200006685 B ZA200006685 B ZA 200006685B
Authority
ZA
South Africa
Prior art keywords
pll
peg
targeting moiety
lysine
gene
Prior art date
Application number
ZA200006685A
Other languages
English (en)
Inventor
Jong Sang Park
Young-Hun Choi
Feng Liu
Original Assignee
Expression Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Genetics Inc filed Critical Expression Genetics Inc
Publication of ZA200006685B publication Critical patent/ZA200006685B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyamides (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
ZA200006685A 1998-05-20 2000-11-16 A hepatocyte targeting polyethylene Glyco-grafted poly-l-lysine polymeric gene carrier. ZA200006685B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8607298P 1998-05-20 1998-05-20

Publications (1)

Publication Number Publication Date
ZA200006685B true ZA200006685B (en) 2001-07-13

Family

ID=22196073

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200006685A ZA200006685B (en) 1998-05-20 2000-11-16 A hepatocyte targeting polyethylene Glyco-grafted poly-l-lysine polymeric gene carrier.

Country Status (17)

Country Link
US (1) US6177274B1 (es)
EP (1) EP1083882B1 (es)
JP (1) JP2002515418A (es)
KR (1) KR20010071279A (es)
CN (1) CN1333678A (es)
AT (1) ATE411049T1 (es)
AU (1) AU4193199A (es)
BR (1) BR9911062A (es)
CA (1) CA2329147A1 (es)
DE (1) DE69939740D1 (es)
FI (1) FI20002539A (es)
IL (1) IL139761A0 (es)
MX (1) MXPA00011312A (es)
NO (1) NO20005809D0 (es)
TR (1) TR200003441T2 (es)
WO (1) WO1999059546A1 (es)
ZA (1) ZA200006685B (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040510A1 (en) 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
EP1063254A1 (de) * 1999-06-25 2000-12-27 Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung Copolymere für den Transport von Nukleinsäuren in die Zelle
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
EP1286699A2 (en) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
US20020042388A1 (en) * 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
KR100553376B1 (ko) * 2001-02-28 2006-02-20 재단법인서울대학교산학협력재단 다양이온 초가지성 폴리아미노에스테르
US6544954B1 (en) 2002-02-19 2003-04-08 Oliver Yoa-Pu Hu Stable galactose injection solutions
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
AR037006A1 (es) * 2002-06-20 2004-10-20 S I G Sist S De Identificacion Marcador de objetos a identificar consistente en al menos un fragmento de adn.
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
WO2005012407A2 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
JP2005151891A (ja) * 2003-11-27 2005-06-16 Japan Science & Technology Agency 細胞認識糖側鎖を持つ多糖系遺伝子キャリアー
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20060229267A1 (en) * 2004-06-01 2006-10-12 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US7304045B2 (en) * 2004-10-05 2007-12-04 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells
US8318198B1 (en) 2004-10-05 2012-11-27 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8318200B1 (en) 2004-10-05 2012-11-27 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US7985426B1 (en) 2004-10-05 2011-07-26 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells and delivery means
US8198246B1 (en) 2004-10-05 2012-06-12 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US7348026B2 (en) * 2004-10-05 2008-03-25 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
EP1957044B1 (en) 2005-12-01 2013-03-13 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP3000480A1 (en) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
CN101138636B (zh) * 2006-09-05 2010-05-12 中国科学院上海药物研究所 一种基因药物的输送系统及其制备方法
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
AU2008298592A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
WO2009062084A2 (en) * 2007-11-07 2009-05-14 University Of Utah Research Foundation Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery
US20090130752A1 (en) * 2007-11-07 2009-05-21 University Of Utah Research Foundation Biodegradable poly(disulfide amine)s for gene delivery
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
HUE035770T2 (en) * 2008-06-16 2018-05-28 Pfizer Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles
KR20110024642A (ko) * 2009-09-02 2011-03-09 삼성전자주식회사 디스플레이장치 및 그 제어 방법
JP5510808B2 (ja) * 2010-03-10 2014-06-04 独立行政法人産業技術総合研究所 有機ナノチューブからなる核酸導入剤
US20110229528A1 (en) * 2010-03-12 2011-09-22 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
US20130149783A1 (en) * 2010-03-16 2013-06-13 James William Yockman Cleavable modifications to reducible poly (amido ethylenimines)s to enhance nucleotide delivery
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN101974152B (zh) * 2010-09-28 2012-07-11 山东大学 一种类脂-阳离子聚合物及其制备方法
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
WO2012051457A1 (en) * 2010-10-14 2012-04-19 Nitto Denko Corporation Nucleic acid delivery compounds
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3971287A1 (en) 2013-07-11 2022-03-23 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
JP2017500865A (ja) 2013-12-19 2017-01-12 ノバルティス アーゲー レプチンmRNAの組成物および製剤
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
KR20180063885A (ko) 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
WO2018232006A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
CA3079543A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
EP3714048A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
JP7267609B2 (ja) * 2018-01-30 2023-05-02 国立大学法人大阪大学 抗がん剤
EP4242307A3 (en) 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US20220110966A1 (en) 2018-09-02 2022-04-14 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
AU2019337637A1 (en) 2018-09-13 2021-04-22 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
US20220243182A1 (en) 2018-09-13 2022-08-04 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
JP2022500444A (ja) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ1ファミリー、ポリペプチドa1をコードするポリヌクレオチド
MA53734A (fr) 2018-09-27 2021-08-04 Modernatx Inc Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
JP2023527875A (ja) 2020-06-01 2023-06-30 モダーナティエックス・インコーポレイテッド フェニルアラニンヒドロキシラーゼバリアント及びその使用
CA3199784A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
JP2024512026A (ja) 2021-03-24 2024-03-18 モデルナティエックス インコーポレイテッド オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240175033A1 (en) 2021-03-26 2024-05-30 Mina Therapeutics Limited TMEM173 saRNA Compositions and Methods of Use
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
EP4183884A1 (en) 2021-11-19 2023-05-24 Branca Bunus Limited A method of preparing a fraction of a starting polymer vector for gene therapy
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757760B2 (ja) * 1987-06-05 1995-06-21 宇部興産株式会社 生体由来物質の固定化方法
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
SE469256B (sv) * 1991-02-18 1993-06-14 Medscand Ab Rengoeringsprodukt
ZA926185B (en) * 1991-08-22 1993-03-01 Merrell Dow Pharma Novel orally-active elastase inhibitors.
US5578442A (en) * 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5733762A (en) * 1994-04-28 1998-03-31 I.D.M. Immuno-Designed Molecules Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells
WO1996021036A2 (en) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
CA2220339C (en) * 1995-05-10 2009-10-13 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
JPH09157325A (ja) * 1995-12-07 1997-06-17 Meiji Milk Prod Co Ltd オリゴ糖誘導体
AU717660B2 (en) * 1995-12-18 2000-03-30 Angiodevice International Gmbh Crosslinked polymer compositions and methods for their use
JP3808938B2 (ja) * 1996-07-16 2006-08-16 久光製薬株式会社 核酸運搬体
JPH1087815A (ja) * 1996-08-22 1998-04-07 Enzon Inc ポリアルキレンオキシドカルボン酸の改良製造方法
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery

Also Published As

Publication number Publication date
KR20010071279A (ko) 2001-07-28
IL139761A0 (en) 2002-02-10
FI20002539A (fi) 2001-01-19
NO20005809D0 (no) 2000-11-17
MXPA00011312A (es) 2003-04-22
CN1333678A (zh) 2002-01-30
US6177274B1 (en) 2001-01-23
ATE411049T1 (de) 2008-10-15
DE69939740D1 (de) 2008-11-27
BR9911062A (pt) 2001-02-06
CA2329147A1 (en) 1999-11-25
TR200003441T2 (tr) 2001-04-20
EP1083882A4 (en) 2004-08-18
JP2002515418A (ja) 2002-05-28
WO1999059546A1 (en) 1999-11-25
AU4193199A (en) 1999-12-06
EP1083882B1 (en) 2008-10-15
EP1083882A1 (en) 2001-03-21

Similar Documents

Publication Publication Date Title
IL139761A0 (en) A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier
US8431545B2 (en) Copolymer including uncharged hydrophilic block and cationic polyamino acid block having hydrophobic group in part of side chains, and use thereof
US20210187005A1 (en) Pharmaceutical composition
US20050019923A1 (en) Dendrimers for use in targeted delivery
US8546487B2 (en) Cationic poly (amino acids) and uses thereof
Kawano et al. Long circulation of intravenously administered plasmid DNA delivered with dendritic poly (L-lysine) in the blood flow
WO2004087931A1 (en) Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
Sakae et al. Highly efficient in vivo gene transfection by plasmid/PEI complexes coated by anionic PEG derivatives bearing carboxyl groups and RGD peptide
CA2362994A1 (en) Core-shell tectodendrimers
CA2562938C (en) Peg-functional nucleic acid conjugate
EP2462938B1 (en) Anionic polymer, polyion complex and ternary polymer composite using anionic polymer, and pharmaceutical composition
EP1675888B1 (en) Cationic polymers having degradable crosslinks
EP4037716A1 (en) Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics
Cherng et al. The characteristics and transfection efficiency of PEI modified by biodegradable poly (β-amino ester)
WO2004083450A3 (en) Hyperbranched dendron and methods of synthesis and use thereof
Arote et al. Folate conjugated poly (ester amine) for lung cancer therapy
Song et al. Synthesis and antitumor activity of poly (organophosphazene)/doxorubicin conjugates
US20200407502A1 (en) Cationic polymers with d-fructose substituents
Lee Design, Synthesis, and Structure-Bioactivity Characterization of Novel Carbohydrate-Based Polymers as Nucleic Acid Delivery Vectors
Lungwitz Polyethylenimine-derived gene carriers and their complexes with plasmid DNA. Design, synthesis and characterization